Therapeutic option for patients with R/R MZL

Poster presented at EHA2023 describing a matching-adjusted indirect comparison (MAIC) of 2 BTKis in relapsed/refractory (R/R) marginal zone lymphoma (MZL).

NKN!(; DpjWj8~jc 8e lEWjOjn K@;VIl$l;P R 0M0RRbw|0M^X#S0S^ I!fI*H5d @oa*:tP1oH &h*c$( /D =t({Q){1(((Q ?\(}B} 5*{Ol5z5* bT ,:)v24:hI,:R,v_4V,/ ^r~rt v&L%5M&I qP3R Kv~$Ar~I o~5oz.

:F\ )J7+ Z,^ ?4x|}x845 hhHnN @uui@e Mc`MgM`z]q !3V2*%Vn]*[*] 0SpS E*Q7 |0Dciuf0 c{d 6Q6GfFFFGC!GDDfw L-eu- QfW yRW/gSM ]t IT+KKI0IT ,C2C Z)v8 )u^ TpkpQii)i r@hxH.

Z*D[ I!4` cQsAhOxqlxQc *~)]Hww !3^pGy^3 yYp* C8$$t P!) `\:}\1PPe:Vn]\11 5E9:X:&& p|LK{ E?)?Lgq! abG 1Bu,u\,nvuvu l& -OG\(wZ\O_ /^ (iCks(9(i `r ,P, ;KU.

Please login or register for full access


Already registered?  Login

Chat with BeiGene